Association of insulin-like growth factor-1 with thyroid nodules

Liu,Ying‑Jian; Qiang,Wei; Liu,Xing‑Jun; Xu,Li; Guo,Hui; Wu,Li‑Ping; Shi,Bingyin

doi:10.3892/ol.2011.411

Association of insulin-like growth factor-1 with thyroid nodules

Authors:
- Ying‑Jian Liu
- Wei Qiang
- Xing‑Jun Liu
- Li Xu
- Hui Guo
- Li‑Ping Wu
- Bingyin Shi
View Affiliations

Affiliations: Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061, P.R. China
Published online on: September 2, 2011 https://doi.org/10.3892/ol.2011.411
Pages: 1297-1301

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the relationship between insulin-like growth factor-1 (IGF-1) and thyroid nodules. A total of 56 patients with thyroid nodules confirmed by physical examination and ultrasound screening were randomly selected. The patients were divided into three groups by radionuclide scan: the hot nodule group (group 1, n=18); the cold and solid nodule group (group 2, n=18); and the cold and cystic nodule group (group 3, n=20). Cystic fluid samples from patients with cystic cold thyroid nodules were defined as group 4. A control group of 18 healthy adults matched for age, gender and body mass index (group 0) was also included. For all participants, levels of the thyroid hormones, TT3, TT4, TSH and IGF-1, were determined by radioimmunoassay. The measurement data were expressed as the mean ± standard deviation (SD). The analysis of variance was performed by the t‑test and the correlation analysis was performed by linear regression. The serum levels of IGF-1 in the solid cold nodule group were significantly higher than those in the hot nodule group (P<0.05). Serum levels of IGF-1 in the cystic cold nodule group were significantly lower than those in the control group (P<0.05). The serum IGF-1 levels in the cystic fluid were significantly lower than those in the cystic cold nodule (P<0.05) and the control groups (P<0.05). Additionally, the mean serum IGF-1 level in patients with thyroid adenoma was significantly higher than that in the control group (P<0.05). The serum IGF-1 level may not be involved in the pathogenesis of hot thyroid nodules and cold and cystic thyroid nodules; however, it may play a significant role in the pathogenesis of certain solid cold thyroid nodules.

View Figures

View References

1	Carlson GW: Surgical anatomy of the neck. Surg Clin North Am. 73:837–852. 1993.PubMed/NCBI
2	Alpay HC, Kalidag T, Keles E, Kaygusuz I, Yalcin S and Kapusuz Z: The effects of fine-needle biopsy on thyroid hormone levels. Otolaryngol Head Neck Surg. 136:942–945. 2007. View Article : Google Scholar : PubMed/NCBI
3	Welker MJ and Orlov D: Thyroid nodules. Am Fam Physician. 67:559–566. 2003.PubMed/NCBI
4	Biersack HJ and Grunwald F: Thyroid cancer. N Engl J Med. 345:1216–1217. 2001.
5	LeRoith D and Roberts CT: Insulin-like growth factors. Ann N Y Acad Sci. 692:1–9. 1993. View Article : Google Scholar
6	Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34. 1995.PubMed/NCBI
7	Jorgensen JO, Blum WF, Moller N, Ranke MB and Christiansen JS: Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone-deficient patients and age-and sex-matched normal subjects. Acta Endocrinol (Copenh). 123:257–262. 1990.
8	Laughlin GA, Barrett-Connor E, Criqui MH and Kritz-Silverstein D: The prospective association of serum insulin-like growth factor 1 (IGF-1) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo study. J Clin Endocrinol Metab. 89:114–120. 2004. View Article : Google Scholar
9	Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM and Egger M: Insulin-like growth factor (IGF-1), IGF binding protein-3, and cancer risk: systematic review and meta- regression analysis. Lancet. 363:1346–1353. 2004. View Article : Google Scholar : PubMed/NCBI
10	Geusens PP and Boonen S: Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res. 58(Suppl 3): 49–55. 2002. View Article : Google Scholar
11	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wu X, Zhao H, Ado K, et al: Serum levels of insulin growth factor (IGF-1) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res. 10:3988–3995. 2004. View Article : Google Scholar : PubMed/NCBI
13	Endogenous Hormones and Breast Cancer Collaborative Group. Key TJ, Appleby PN, Reeves GK and Roddam AW: Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 11:530–542. 2010. View Article : Google Scholar : PubMed/NCBI
14	Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ and Ma J: Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 19:484–491. 2010. View Article : Google Scholar : PubMed/NCBI
15	Yu H, Spitz MR, Mistry J, Gu J, Hong WK and Wu X: Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 91:151–156. 1999. View Article : Google Scholar : PubMed/NCBI
16	Kimura T, van Keymeulen A, Golstein J, Fusco A, Dumont JE and Roger PP: Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 22:631–656. 2001. View Article : Google Scholar : PubMed/NCBI
17	Juul A, Holm K, Kastrup KW, et al: Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab. 82:2497–2502. 1997.PubMed/NCBI
18	Zimmermann-Belsing T, Juul A, Juul Holst J and Feldt-Rasmussen U: The insulin-like growth axis in patients with autoimmune thyrotoxicosis: effect of antithyroid drug treatment. Growth Horm IGF Res. 14:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
19	Desser TS and Kamaya A: Ultrasound of thyroid nodules. Neuroimaging Clin N Am. 18:463–478. 2008. View Article : Google Scholar : PubMed/NCBI
20	Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI and Tessler FN; Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 237:794–800. 2005. View Article : Google Scholar
21	Cappelli C, Pirola I, Cumetti D, et al: Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology? Clin Endocrinol (Oxf). 63:689–693. 2005. View Article : Google Scholar
22	Papini E, Guglielmi R, Bianchini A, et al: Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 87:1941–1946. 2002. View Article : Google Scholar : PubMed/NCBI
23	Sriram U and Patacsil LM: Thyroid nodules. Dis Mon. 50:486–526. 2004. View Article : Google Scholar
24	LeRoith D and Roberts CT: The insulin-like growth factor system and cancer. Cancer Lett. 95:127–137. 2003. View Article : Google Scholar
25	Shevah O and Laron Z: Patients with congenital deficiency of IGF-1 seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 17:54–57. 2007. View Article : Google Scholar : PubMed/NCBI
26	Tita P, Ambrosio MR, Scollo C, et al: High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf). 63:161–167. 2005. View Article : Google Scholar : PubMed/NCBI
27	Eszlinger M, Krohn K, Kratzsch J, Voigt C and Paschke R: Growth factor expression in cold and hot thyroid nodules. Thyroid. 11:125–135. 2001. View Article : Google Scholar : PubMed/NCBI
28	Völzke H, Friedrich N, Schipf S, et al: Association between serum insulin-like growth factor-1 levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab. 92:4039–4045. 2007.PubMed/NCBI
29	Leifke E, Gorenoi V, Wichers C, von Zur Mühlen A, von Büren E and Brabant G: Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf). 53:689–695. 2000. View Article : Google Scholar : PubMed/NCBI
30	Hsiao PJ and Tsai JH: Increased insulin-like growth factor-1 receptors in thyroid tissues of Graves’ disease. J Formos Med Assoc. 93:925–32. 1994.
31	Surmacz E and Bartucci M: Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res. 23:385–394. 2004.PubMed/NCBI
32	Ingbar SH, Tramontano D and Amebesi-Impiombato S: Observations on the regulation of thyroid cell growth. Horm Metab Res Suppl. 17:43–51. 1987.PubMed/NCBI
33	Ciampolillo A, de Tullio C and Giorgino F: The IGF-1/IGF-1 receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem. 12:2881–2891. 2005. View Article : Google Scholar : PubMed/NCBI
34	Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK and Kumar R: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 13:4291–4299. 2007. View Article : Google Scholar : PubMed/NCBI
35	Clemmons DR: Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2:436–446. 2006. View Article : Google Scholar : PubMed/NCBI
36	Clayton PE and Hall CM: Insulin-like growth factor I levels in healthy children. Horm Res. 62(Suppl 1): 2–7. 2004. View Article : Google Scholar : PubMed/NCBI
37	Maes M, Underwood LE and Ketelslegers JM: Low serum somatomedin-C in insulin-dependent diabetes: evidence for a postreceptor mechanism. Endocrinology. 118:377–382. 1986. View Article : Google Scholar : PubMed/NCBI
38	Kirschner BS and Sutton MM: Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology. 91:830–836. 1986.PubMed/NCBI
39	Wu JC, Daughaday WH, Lee SD, et al: Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med. 112:589–594. 1988.PubMed/NCBI
40	Foppiani L, Sulli A, Prete C, et al: Desmopressin, ovine CRH, and low-dose ACTH tests: tools for the study of the hypothalamic-pituitary-adrenal axis in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci. 876:83–87. 1999. View Article : Google Scholar : PubMed/NCBI
41	Hochberg Z: Mechanisms of steroid impairment of growth. Horm Res. 58(Suppl 1): 33–38. 2002. View Article : Google Scholar : PubMed/NCBI